Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has completed a $1 million placement to support key 2026 technical ...

St. Louis will host July workshops and a virtual meeting to present draft zoning development standards, share map updates, ...

Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, ...

PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi ...

A new generation of reversible male contraceptives is advancing through clinical trials to expand family planning options.

The new agreement creates more competition but could leave officials "looking over their shoulders." ...

(Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, ...

Cities and towns throughout the United States vary drastically in terms of how well they are managed and operated on a daily ...

AP-101 is an investigational human-derived antibody that selectively targets the misfolded, toxic form of superoxide dismutase 1 (SOD1) to disrupt the progressive spread of ALS. The goal of this ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...